Answers are grounded in this paper and cite their sources.
Degradation products of phospholipase A₂ (PLA₂), the major allergen of honeybee venom, were prepared by peptic digestion of the enzyme and fractionated by molecular exclusion chromatography. The largest of the isolated products, P-l, was found to be a centrally nicked PLA₂ molecule with a loss of several amino acids. It was examined for its antigenic, immunogenic and immunosuppressive properties. This peptic product was unable to block antigen-antibody reactions between PLA₂ and anti-PLA₂ antibodies and was incapable of inducing passive cutaneous anaphylaxis in rat skin sensitized with mouse anti-PLA₂ IgE antibodies. BDF₁ female mice injected intravenously with P-1 exhibited suppressed IgG and IgE anti-PLA₂ responses to a subsequent PLA₂ immunization. Intravenous administration of P-1 to mice with ongoing immune response to PLA₂resulted in decline of antigen-specific IgE titers. Transfer of splenic T cells from mice injected with P-1 into naive recipients caused profound suppression of the response to subsequent immunization with PLA₂ indicating presence of PLA₂-specific T suppressor cells. These results indicate that a degradation product of PLA₂ prepared by peptic digestion lost antigenic and immunogenic properties of the intact enzyme but retained immunosuppressive properties, thus offering a novel approach to allergen immunotherapy.
No takes yet. Share an insight, caveat, or question.
Pesce et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: